Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

Pfizer turns to app to overcome rare disease enrollment bottleneck

Pfizer is experimenting with a mobile app to enroll rare disease patients in a study. The trial is comparing the DNA of people with congenital analgesia to unaffected family members.

Early Medidata backer plans $150M digital-health fund

Milestone Venture Partners is readying a digital-health investment fund. The VC shop is aiming to raise $150 million from biopharma companies and others to invest in up to 20 early-stage digital health companies.

Autism Speaks to make Google-underpinned genomics database freely available

Autism Speaks has released details of the genome sequencing database it is building on Google's cloud platform. The plan is to sequence the whole genomes of 10,000 people in families affected by autism and make the resulting database freely available to researchers.

Transcriptic offers Y Combinator biotechs $20,000 credit for its robotic labs

The 10 biotechs in the latest batch of Y Combinator startups--as well as those that have already graduated from the incubator--will receive $20,000 to spend at Transcriptic's automated life science laboratory.

Flatiron maintains dealmaking pace with patient-reported outcome data hookup

One week after striking a deal with Foundation Medicine, Google Ventures-backed cancer analytics firm Flatiron Health has hooked up with Vector Oncology to advance its clinical research and real-world evidence activities.

Paul Allen donates $100M to create cell science institute

Microsoft co-founder Paul Allen has once again dipped into his personal fortune to advance science. The latest venture sees Allen donate $100 million to create a cell science center with a heavy reliance on IT.

Documents reveal FDA's use of computer forensics to uncover data falsification

In 2011, a Sun Pharma technician gave into temptation, hit the delete key and generated new, positive data from another sample within the same batch. In 2013, the FDA uncovered what had happened and tasked its computer forensics experts with finding other such events. The team discovered 5,301 more deleted chromatography results from the same facility.

Ex-Pfizer SVP named CEO of BioClinica

BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer, where he worked as senior vice president and worldwide head of development operations.

Flatiron Health teams with Foundation Medicine to develop oncology platform

Flatiron Health has revealed part of how it plans to develop into the disruptive force in cancer drug R&D that investors envisaged when they gave it $130 million in May. The latest piece of the plan is a deal with testing firm Foundation Medicine, which will contribute genomic profiling data to a cancer analytics platform.

Hackers use Wall Street know-how to steal stock-moving biotech info

Biotech IT security teams were just presented with another headache. A team of Western, Wall Street insiders is believed to be breaking into biopharma company emails in pursuit of information on drug development results, takeovers and other events likely to affect share prices.